Unlocking the secrets of cancer stem cells: Immune checkpoint inhibitors face their formidable foes.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 37267909.
- Also identified by DOI 10.1016/j.stem.2023.05.011.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this issue of Cell Stem Cell, Beziaud et al.<sup>1</sup> show that immunotherapy induces stem-like properties in models of breast cancer. Strikingly, T-cell-derived IFNγ promotes cancer stem cell (CSC) phenotypes, therapy resistance, and metastasis. Targeting BCAT1 downstream offers promise for enhancing immunotherapy outcomes.
Medical subject headings
- Immune Checkpoint Inhibitors
- Neoplasms